Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "Waśko-Grabowska, Anna" wg kryterium: Autor


Wyświetlanie 1-2 z 2
Tytuł:
Hypothyroidism caused by cabozantinib therapy of clear cell renal cell carcinoma – case report, own experience
Autorzy:
Buraczewska, Agnieszka
Kardas, Joanna
Młot, Beata
Solarek, Wojciech
Waśko-Grabowska, Anna
Powiązania:
https://bibliotekanauki.pl/articles/1062936.pdf
Data publikacji:
2017
Wydawca:
Medical Education
Tematy:
cabozantinib
hypothyroidism
renal cell carcinoma
Opis:
Cabozantinib, the latest available in Poland medication for the treatment of renal cell carcinoma, registered in this indication by the European Medicines Agency (EMA) in September 2016, has been available in several cancer centers in Poland since November 2016 as part of the expanded access program. Primary hypothyroidism is a common complication during thyrosine kinase inhibitors (TKI) treatment, although there are few reports of its occurrence during treatment with cabozantinib, which belongs to this medication group. We present a case of rapid development of clinically apparent hypothyroidism after cabozantinib treatment and report data on this complication in the group of our patients.
Źródło:
OncoReview; 2017, 7, 3; 121-125
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The evaluation of the efficacy and toxicity of targeted treatment in non-small cell lung cancer patients – single centre experience
Autorzy:
Kardas, Joanna
Buraczewska, Agnieszka
Chrom, Paweł
Waśko-Grabowska, Anna
Młot, Beata
Szczylik, Cezary
Powiązania:
https://bibliotekanauki.pl/articles/773534.pdf
Data publikacji:
2017
Wydawca:
Medical Education
Tematy:
endothelial growth factor receptor
non-small cell lung cancer
tyrosine kinase inhibitor
Opis:
Introduction: Tyrosine kinase inhibitors (TKI) are the standard of treatment in patients with advanced non-small cell lung cancer (NSCLC) with EGFR (endothelial growth factor receptor) gene activating mutation. Objective: The evaluation of the efficacy and toxicity of TKI drugs in NSCLC patients treated in single centre. Material and methods: NSCLC patients treated with TKI (gefitinib, erlotynib, afatinib) between 2012– 2016 were retrospectively analysed. We evaluated: overall response rate (ORR) which is the sum of complete responses (CR) and partial remissions (PR), progression free survival (PFS), overall survival (OS) and adverse events (AE) according to CTCAE (Common Terminology Criteria for Adverse Events) scale. Results: The study group were 16 patients ORR was 50% (CR: 1, PR: 7). Median PFS and OS was 8,7 and 22,9 months respectively. Adverse events observed mainly in stage 1 and 2 were related to hyponatraemia, hyperbilirubinemia, skin toxicity and mucositis. There was one death reported due to infectious complications. Conclusion: The efficacy and toxicity of TKI in study group were found to be similar to those described in the literature.
Źródło:
OncoReview; 2017, 7, 2; 92-97
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies